Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
The current status and future directions of myxoma virus, a master in immune evasion

The current status and future directions of myxoma virus, a master in immune evasion,10.1186/1297-9716-42-76,Veterinary Research,Bart Spiesschaert,Gra

Edit
The current status and future directions of myxoma virus, a master in immune evasion  
BibTex | RIS | RefWorks Download
Myxoma virus (MYXV) gained importance throughout the twentieth century because of the use of the highly virulent Standard Laboratory Strain (SLS) by the Australian government in the attempt to control the feral Australian population of Oryctolagus cuniculus (European rabbit) and the subsequent illegal release of MYXV in Europe. In the European rabbit, MYXV causes a disease with an exceedingly high mortality rate, named myxomatosis, which is passively transmitted by biting arthropod vectors. MYXV still has a great impact on European rabbit populations around the world. In contrast, only a single cutaneous lesion, restricted to the point of inoculation, is seen in its natural long-term host, the South-American Sylvilagus brasiliensis and the North-American S. Bachmani. Apart from being detrimental for European rabbits, however, MYXV has also become of interest in human medicine in the last two decades for two reasons. Firstly, due to the strong immune suppressing effects of certain MYXV proteins, several secreted virus-encoded immunomodulators (e.g. Serp-1) are being developed to treat systemic inflammatory syndromes such as cardiovascular disease in humans. Secondly, due to the inherent ability of MYXV to infect a broad spectrum of human cancer cells, the live virus is also being developed as an oncolytic virotherapeutic to treat human cancer. In this review, an update will be given on the current status of MYXV in rabbits as well as its potential in human medicine in the twenty-first century. Table of contents Abstract 1.  The virus 2.  History 3.  Pathogenesis and disease symptoms 4.  Immunomodulatory proteins of MYXV 4.1.  MYXV proteins with anti-apoptotic functions 4.1.1.  Inhibition of pro-apoptotic molecules 4.1.2.  Inhibition by protein-protein interactions by ankyrin repeat viral proteins 4.1.3.  Inhibition of apoptosis by enhancing the degradation of cellular proteins 4.1.4.  Inhibition of apoptosis by blocking host Protein Kinase R (PKR) 4.2.  MYXV proteins interfering with leukocyte chemotaxis 4.3.  MYXV serpins that inhibit cellular pro-inflammatory or pro-apoptotic proteases 4.4.  MYXV proteins that interfere with leukocyte activation 4.5.  MYXV proteins with sequence similarity to HIV proteins 4.6.  MYXV proteins with unknown immune function 5.  Vaccination strategies against myxomatosis 5.1.  Current MYXV vaccines 5.2.  Vaccination campaigns to protect European rabbits in the wild 6.  Applications of myxoma virus for human medicine 6.1.  MYXV proteins as therapeutics for allograft vasculopathy and atherosclerosis 6.2.  Applications for MYXV as a live oncolytic virus to treat cancer 7.  Discussion and Conclusions 8.  List of Abbreviations References Author Details Authors' contributions Competing interests Figure Legends Acknowledgements
Journal: Veterinary Research - VET RES , vol. 42, no. 1, pp. 1-18, 2011
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Share this on